Treatment and detection of ALK-rearranged NSCLC.

Details

Serval ID
serval:BIB_713154EEABF5
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment and detection of ALK-rearranged NSCLC.
Journal
Lung Cancer (amsterdam, Netherlands)
Author(s)
Peters S., Taron M., Bubendorf L., Blackhall F., Stahel R.
ISSN
1872-8332 (Electronic)
ISSN-L
0169-5002
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
81
Number
2
Pages
145-154
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
The recent approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC) in the US and other countries has provoked intense interest in ALK rearrangements as oncogenic drivers, and promises to revolutionise the way in which NSCLC is diagnosed and treated. Here, we review clinical data to date for the use of crizotinib to treat patients with advanced, ALK-positive NSCLC and consider issues surrounding the detection of ALK-positivity including the use of fluorescence in situ hybridisation and the other potential techniques available, and their suitability for ALK screening. We also discuss the emergence of resistance to crizotinib therapy and the range of other ALK inhibitors currently in development.
Pubmed
Web of science
Create date
22/08/2013 16:25
Last modification date
20/08/2019 14:29
Usage data